Taiwan Advanced Nanotech

Taiwan Advanced Nanotech EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Taiwan Advanced Nanotech (6797.TWO) as of Nov 11, 2026 is -19.24. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -2.78 — a change of 592.48% (lower).

EV/FCF

-19.24

YoY

592.48%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Taiwan Advanced Nanotech is 2025 -19.24 . EV/FCF (Enterprise Value to Free Cash Flow) of Taiwan Advanced Nanotech was 2024 -2.78 . It decreases by 592.48% lower compared to the previous year.

The Taiwan Advanced Nanotech EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-31.89 TWD
Jan 1, 2019
-11.20 TWD
Jan 1, 2020
-0.02 TWD
Jan 1, 2021
-0.27 TWD
Jan 1, 2022
-1.03 TWD
Jan 1, 2023
-0.04 TWD
Jan 1, 2024
-2.78 TWD
Jan 1, 2025
-19.24 TWD
The Taiwan Advanced Nanotech EV/FCF history
YEAREV/FCFYoY
-19.24+592.48%
-2.78+6,328.82%
-0.04-95.79%
-1.03+284.39%
-0.27+1,293.36%
-0.02-99.83%
-11.20-64.88%
-31.89+300.69%
-7.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Taiwan Advanced Nanotech Stock analysis

What does Taiwan Advanced Nanotech do? Taiwan Advanced Nanotech, Inc. generates revenue through the sale of nucleic acid purification products, including SLA series, Maelstrom series, and LH series instruments designed for DNA/RNA extraction. The company also sells specialized reagents such as virus nucleic acid extraction reagent 665 series, blood nucleic acid extraction reagent 611/61E series, and tissue nucleic acid extraction reagent 6T2/6K2 series. These products are marketed to customers in Taiwan, South Korea, and China, with sales primarily focused on laboratory and medical applications requiring nucleic acid processing. The company's product portfolio targets research institutions, diagnostic laboratories, and healthcare facilities seeking efficient nucleic acid extraction solutions. By offering a range of instruments and reagents tailored to specific extraction needs, Taiwan Advanced Nanotech addresses key segments in the biotechnology and medical diagnostics markets. Sales are distributed across Taiwan, South Korea, and China, reflecting the company's regional market focus. Revenue streams are derived from direct sales of instruments and reagents to end-users in the biotech and healthcare sectors. The SLA, Maelstrom, and LH series instruments serve as core revenue drivers, complemented by recurring reagent sales for ongoing laboratory operations. This dual-product approach ensures steady income from both capital equipment and consumable supplies. Taiwan Advanced Nanotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Taiwan Advanced Nanotech stock

EV/FCF (Enterprise Value to Free Cash Flow) of Taiwan Advanced Nanotech is -19.24 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Taiwan Advanced Nanotech changed from -2.78 to -19.24, representing a 592.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Taiwan Advanced Nanotech since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Taiwan Advanced Nanotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Taiwan Advanced Nanotech

All Key Metrics — Taiwan Advanced Nanotech